Cerulean encouraged by early data
Cerulean Pharma Inc., a Cambridge company that seeks to design and develop nanopharmaceuticals, said it is encouraged by results of early clinical test for its lead drug candidate, CRLX101, which has the potential to treat a common form of lung cancer.
The company gave an update on two years' worth of test data to the American Chemical Society National Meeting & Exposition this week in Boston.
In addition, preliminary results show that Cerulean's technology can help deliver more of a drug to a tumor cell, which can add to the drug's effectiveness, the company said.
In a statement, Cerulean president and chief executive Oliver Fetzer said: "Cerulean has made substantial progress with our nanopharmaceutical platform. Our team is successfully advancing our clinical studies in cancer patients and demonstrating in pre-clinical studies our platform technologies' capabilities. We believe our technologies have broad applicability in advancing new drugs in oncology and other therapeutic areas and overcoming significant clinical hurdles."
- By Email Business Updates newsletter
- By SMS Text "business" to BOSTON (267866)
